SNAP (Serum Vitamin D as a prognostic marker in Covid-19) [COVID-19]

  • Research type

    Research Study

  • Full title

    Serum Vitamin D as a prognostic marker of COVID-19

  • IRAS ID

    283301

  • Contact name

    Sreedhar Subramanian

  • Contact email

    sreedhar.subramanian@liverpoolft.nhs.uk

  • Sponsor organisation

    Liverpool University Hospitals Foundation NHS Trust

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Covid-19 has manifestations ranging from no symptoms to acute respiratory distress syndrome and death. Risk factors for poor outcome include male sex, older age, obesity, co-morbidities such as Diabetes and hypertension and ethnicity. There is also a marked North-South gradient with such higher mortality in countries North of latitude 35. This suggests that Vitamin D may have a possible role in determining outcomes in Covid-19. Vitamin D is well known to have immunomodulatory properties and Vitamin D deficiency is particularly common in Northern latitudes and is associated with elderly, Diabetes, obesity and hypertension, all factors associated with poor outcomes in Covid-19. Furthermore, Vitamin D has been shown in experimental studies to modulate the severe cytokine storm that is seen in severely ill Covid-19 patients (high levels of interleukin-6). We intend to perform an observational study looking at serum Vitamin-D and outcomes in Covid-19 by using residual serum sample from routine sampling of hospitalised Covid-19 patients. We will also include other routinely collected variables that may be of relevance in Covid-19 outcomes (for example: neutrophil-lymphocyte ratio, C-reactive protein, glycemic variability in Diabetes). [Study relying on COPI notice]

  • REC name

    London - Surrey Research Ethics Committee

  • REC reference

    20/HRA/2282

  • Date of REC Opinion

    6 May 2020

  • REC opinion

    Favourable Opinion